<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28574846</article-id><article-id pub-id-type="pmc">5522129</article-id><article-id pub-id-type="publisher-id">17904</article-id><article-id pub-id-type="doi">10.18632/oncotarget.17904</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Polymorphisms in BMP2/BMP4, with estimates of mean lung dose, predict radiation pneumonitis among patients receiving definitive radiotherapy for non-small cell lung cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Ju</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Ting</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gomez</surname><given-names>Daniel R.</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Xianglin</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nguyen</surname><given-names>Quynh-Nhu</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jeter</surname><given-names>Melenda</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Yipeng</given-names></name><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hahn</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Liao</surname><given-names>Zhongxing</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib></contrib-group><aff id="A1"><sup>1</sup> Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA</aff><aff id="A2"><sup>2</sup> The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, 210008, China</aff><aff id="A3"><sup>3</sup> Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China</aff><aff id="A4"><sup>4</sup> Department of Radiation Oncology, Yuhuangding Hospital, Shandong, 264000, China</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Zhongxing Liao, <email>zliao@mdanderson.org</email></corresp></author-notes><pub-date pub-type="collection"><day>27</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>17</day><month>5</month><year>2017</year></pub-date><volume>8</volume><issue>26</issue><fpage>43080</fpage><lpage>43090</lpage><history><date date-type="received"><day>28</day><month>2</month><year>2017</year></date><date date-type="accepted"><day>7</day><month>4</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2017 Yang et al.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License</ext-link> (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>Single nucleotide polymorphisms (SNPs) in <italic>TGF&#x003b2;1</italic> can predict the risk of radiation pneumonitis (RP) in patients with non-small cell lung cancer (NSCLC) after definitive radiotherapy. Here we investigated whether SNPs in TGF&#x003b2; superfamily members <italic>BMP2</italic> and <italic>BMP4</italic> are associated with RP in such patients. In total, we retrospectively analyzed 663 patients given &#x02265; 60 Gy for NSCLC. We randomly assigned 323 patients to the training cohort and 340 patients to the validation cohort. Potentially functional and tagging SNPs of <italic>BMP2</italic> (rs170986, rs1979855, rs1980499, rs235768, rs3178250) and <italic>BMP4</italic> (rs17563, rs4898820, rs762642) were genotyped. The median of mean lung dose (MLD) was 17.9 Gy (range, 0.15&#x02013;32.74 Gy). Higher MLD was strongly associated with increased risk of grade &#x02265; 2 RP (hazard ratio [HR]=2.191, 95% confidence interval [CI] = 1.680&#x02013;2.856, <italic>P</italic> &#x0003c; 0.001) and grade &#x02265; 3 RP (HR = 4.253, 95% CI = 2.493&#x02013;7.257, <italic>P</italic> &#x0003c; 0.001). In multivariate analyses, <italic>BMP2</italic> rs235768 AT/TT was associated with higher risk of grade &#x02265; 2 RP (HR = 1.866, 95% CI = 1.221&#x02013;2.820, <italic>P</italic> = 0.004 vs. AA) both in training cohort and validation cohort. Similar results were observed for <italic>BMP2</italic> rs1980499. <italic>BMP2</italic> rs3178250 CT/TT was associated with lower risk of grade &#x02265; 3 RP (HR = 0.406, 95% CI = 0.175&#x02013;0.942, <italic>P</italic> = 0.036 vs. CC) in the pooled analysis. Adding the rs235768 and rs1980499 SNPs to a model comprising age, performance status, and MLD raised the Harrell's <italic>C</italic> for predicting grade &#x02265; 2 RP from 0.6117 to 0.6235 (<italic>P</italic> = 0.0105). SNPs in <italic>BMP2</italic> can predict grade &#x02265; 2 or 3 RP after radiotherapy for NSCLC and improve the predictive power of MLD model. Validation is underway through an ongoing prospective trial.</p></abstract><kwd-group><kwd>NSCLC</kwd><kwd>BMP2</kwd><kwd>radiation pneumonitis</kwd><kwd>polymorphism</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>Lung cancer is the leading cause of cancer death worldwide, and non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases [<xref rid="R1" ref-type="bibr">1</xref>]. Approximately 70% of patients with NSCLC have locally advanced disease or distant metastases at diagnosis [<xref rid="R2" ref-type="bibr">2</xref>]. Radiotherapy is an important treatment modality for patients with locally advanced disease, particularly those with medical conditions that make them ineligible for surgery. However, radiation-induced lung toxicity, including radiation pneumonitis (RP) and subsequent lung fibrosis, limits the therapeutic ratio and can also complicate quality of life for sur<italic>vivo</italic>rs. Dosimetric variables such as mean lung dose (MLD) and V20 (the volume of lung exposed to radiation doses of 20 Gy or more) have been identified as being associated with RP [<xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R4" ref-type="bibr">4</xref>]. However, some patients will still develop RP even when these variables are under the thresholds established for them, implicating the patients&#x02019; genetic makeup in their response to radiotherapy.</p><p>At the cellular and tissue levels, RP is characterized by injury to type I and type II alveolar cells, endothelium, and fibroblasts, followed by infiltration of inflammatory cells, proliferation of type II alveolar cells and fibroblasts, progression through the epithelial-to-mesenchymal transition (EMT), remodeling of extracellular matrix, and deposition of collagen [<xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R6" ref-type="bibr">6</xref>]. The TGF&#x003b2; superfamily includes multifunctional cytokines that have different isoforms and highly specific functions, e.g. wound healing, extracellular matrix remodeling, and EMT [<xref rid="R7" ref-type="bibr">7</xref>]. Patients who develop RP also show increases in levels of the cytokine TGF&#x003b2;1 during radiotherapy [<xref rid="R8" ref-type="bibr">8</xref>]. We previously found that single nucleotide polymorphisms (SNPs) in <italic>TGF&#x003b2;1</italic> could predict the risk of RP among patients receiving radiotherapy as definitive treatment for NSCLC [<xref rid="R9" ref-type="bibr">9</xref>]. A subgroup of the TGF&#x003b2; superfamily, bone morphogenetic proteins (BMPs), is thought to influence inflammatory processes through their chemotactic effects on fibroblasts, myocytes, and inflammatory cells. In addition to the definite role of TGF&#x003b2;1 in inducing EMT, BMP2 and BMP 4 are the best studied for EMT among the 20 different human BMPs. Interestingly, <italic>BMP2</italic> and <italic>BMP4</italic> have opposing functions: <italic>BMP2</italic> exerts pro-inflammatory effects in endothelial activation [<xref rid="R10" ref-type="bibr">10</xref>], whereas <italic>BMP4</italic> has anti-inflammatory effects in airway injury [<xref rid="R11" ref-type="bibr">11</xref>]. Previous study found that BMP2 was decreased and BMP4 was increased in idiopathic lung fibrosis[<xref rid="R12" ref-type="bibr">12</xref>]. Moreover, the ratio between BMPs and TGF&#x003b2;1 correlates strongly with the EMT: increased TGF&#x003b2;1 expression, decreased <italic>BMP2</italic> expression, and increased <italic>BMP4</italic> expression are all associated with induction of the EMT [<xref rid="R12" ref-type="bibr">12</xref>].</p><p>To the best of our knowledge, no studies have investigated potential associations between SNPs in <italic>BMP2</italic> and <italic>BMP4</italic> and the incidence of RP, and no studies have incorporated <italic>BMP</italic> SNPs into existing models based on MLD for predicting the risk of RP (grade &#x02265; 2 or 3) in patients after definitive radiotherapy for NSCLC. To address these gaps, we selected 8 potentially functional and tagging SNPs in <italic>BMP2</italic> (rs170986, rs1979855, rs1980499, rs235768, and rs3178250) and in <italic>BMP4</italic> (rs17563, rs4898820, and rs762642). Our hypothesis was that these SNPs in <italic>BMP2</italic> and <italic>BMP4</italic> are associated with incidence of RP in such patients and that incorporating these SNPs into an existing predictive model based on MLD could more accurately predict the risk of RP after definitive radiotherapy for NSCLC.</p></sec><sec id="s2"><title>RESULTS</title><sec id="s2_1"><title>Patient characteristics</title><p>The same database was used as our previous study[<xref rid="R13" ref-type="bibr">13</xref>]. Characteristics of the study population are shown in Table <xref ref-type="table" rid="T1">1</xref>. For the total population, the median age of the patients was 66 years (range 35&#x02013;88 years), and most (488 [73.2%]) had stage III NSCLC. The median gross tumor volume (GTV) was 94.8 cm<sup>3</sup> (range 1.5&#x02013;1271.5 cm<sup>3</sup>), the median radiation dose was 69 Gy (range 60&#x02013;87.5 Gy), and the median MLD was 17.9 Gy (range 0.15&#x02013;32.741 Gy). Radiation was delivered as proton beam therapy to 139 patients (20.8%), as intensity-modulated (photon) radiotherapy to 331 patients (49.6%), and as 3-dimensional conformal radiotherapy to 174 patients (26.1%). In addition, 247 patients (36.3%) received induction chemotherapy and 560 patients (84.0%) received concurrent chemotherapy.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Patient characteristics</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">Characteristic</th><th align="center" valign="middle" rowspan="1" colspan="1">Training cohort (<italic>n</italic> = 323)</th><th align="center" valign="middle" rowspan="1" colspan="1">Validation cohort (<italic>n</italic> = 340)</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic> value</th><th align="center" valign="middle" rowspan="1" colspan="1">Pooled analysis (<italic>n</italic> = 663)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Age</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x0003c; 66 (median)</td><td align="center" valign="middle" rowspan="1" colspan="1">160</td><td align="center" valign="middle" rowspan="1" colspan="1">171</td><td align="center" valign="middle" rowspan="1" colspan="1">0.877</td><td align="center" valign="middle" rowspan="1" colspan="1">331</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02265; 66</td><td align="center" valign="middle" rowspan="1" colspan="1">163</td><td align="center" valign="middle" rowspan="1" colspan="1">169</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">332</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Sex</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Male</td><td align="center" valign="middle" rowspan="1" colspan="1">184</td><td align="center" valign="middle" rowspan="1" colspan="1">178</td><td align="center" valign="middle" rowspan="1" colspan="1">0.243</td><td align="center" valign="middle" rowspan="1" colspan="1">362</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Female</td><td align="center" valign="middle" rowspan="1" colspan="1">139</td><td align="center" valign="middle" rowspan="1" colspan="1">162</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">301</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Race</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;White</td><td align="center" valign="middle" rowspan="1" colspan="1">281</td><td align="center" valign="middle" rowspan="1" colspan="1">287</td><td align="center" valign="middle" rowspan="1" colspan="1">0.376</td><td align="center" valign="middle" rowspan="1" colspan="1">568</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Other</td><td align="center" valign="middle" rowspan="1" colspan="1">42</td><td align="center" valign="middle" rowspan="1" colspan="1">53</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">95</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Disease Stage</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;I&#x02013;IIIA</td><td align="center" valign="middle" rowspan="1" colspan="1">139</td><td align="center" valign="middle" rowspan="1" colspan="1">157</td><td align="center" valign="middle" rowspan="1" colspan="1">0.81</td><td align="center" valign="middle" rowspan="1" colspan="1">296</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;IIIB, IV, recurrence</td><td align="center" valign="middle" rowspan="1" colspan="1">160</td><td align="center" valign="middle" rowspan="1" colspan="1">172</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">333</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Tumor Histology</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;SCC</td><td align="center" valign="middle" rowspan="1" colspan="1">116</td><td align="center" valign="middle" rowspan="1" colspan="1">112</td><td align="center" valign="middle" rowspan="1" colspan="1">0.462</td><td align="center" valign="middle" rowspan="1" colspan="1">228</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Non-SCC</td><td align="center" valign="middle" rowspan="1" colspan="1">207</td><td align="center" valign="middle" rowspan="1" colspan="1">228</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">435</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Karnofsky Performance</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x0003c; 80</td><td align="center" valign="middle" rowspan="1" colspan="1">43</td><td align="center" valign="middle" rowspan="1" colspan="1">58</td><td align="center" valign="middle" rowspan="1" colspan="1">0.195</td><td align="center" valign="middle" rowspan="1" colspan="1">101</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02265; 80</td><td align="center" valign="middle" rowspan="1" colspan="1">280</td><td align="center" valign="middle" rowspan="1" colspan="1">282</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">562</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Induction Chemotherapy</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;No</td><td align="center" valign="middle" rowspan="1" colspan="1">211</td><td align="center" valign="middle" rowspan="1" colspan="1">206</td><td align="center" valign="middle" rowspan="1" colspan="1">0.228</td><td align="center" valign="middle" rowspan="1" colspan="1">417</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">112</td><td align="center" valign="middle" rowspan="1" colspan="1">134</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">246</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Smoking Status</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Never</td><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">36</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">55</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Former/Current</td><td align="center" valign="middle" rowspan="1" colspan="1">298</td><td align="center" valign="middle" rowspan="1" colspan="1">298</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">596</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Total Radiation Dose, Gy</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x0003c; 69.03 (median)</td><td align="center" valign="middle" rowspan="1" colspan="1">144</td><td align="center" valign="middle" rowspan="1" colspan="1">184</td><td align="center" valign="middle" rowspan="1" colspan="1">0.010</td><td align="center" valign="middle" rowspan="1" colspan="1">328</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02265; 69.03</td><td align="center" valign="middle" rowspan="1" colspan="1">178</td><td align="center" valign="middle" rowspan="1" colspan="1">151</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">329</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Gross Tumor Volume, cm<sup>3</sup></bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x0003c; 95.2 (median)</td><td align="center" valign="middle" rowspan="1" colspan="1">146</td><td align="center" valign="middle" rowspan="1" colspan="1">160</td><td align="center" valign="middle" rowspan="1" colspan="1">0.418</td><td align="center" valign="middle" rowspan="1" colspan="1">306</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02265; 95.2</td><td align="center" valign="middle" rowspan="1" colspan="1">156</td><td align="center" valign="middle" rowspan="1" colspan="1">148</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">304</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Mean Lung Dose, Gy</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x0003c; 17.9 (median)</td><td align="center" valign="middle" rowspan="1" colspan="1">162</td><td align="center" valign="middle" rowspan="1" colspan="1">157</td><td align="center" valign="middle" rowspan="1" colspan="1">0.579</td><td align="center" valign="middle" rowspan="1" colspan="1">319</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02265; 17.9</td><td align="center" valign="middle" rowspan="1" colspan="1">154</td><td align="center" valign="middle" rowspan="1" colspan="1">165</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">319</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Radiation Modality</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Photon (X-ray)</td><td align="center" valign="middle" rowspan="1" colspan="1">248</td><td align="center" valign="middle" rowspan="1" colspan="1">262</td><td align="center" valign="middle" rowspan="1" colspan="1">0.633</td><td align="center" valign="middle" rowspan="1" colspan="1">510</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Proton</td><td align="center" valign="middle" rowspan="1" colspan="1">71</td><td align="center" valign="middle" rowspan="1" colspan="1">68</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">139</td></tr></tbody></table><table-wrap-foot><p>*<italic>P</italic> values of Pearson chi-square tests.</p></table-wrap-foot></table-wrap><p>We randomized 323 patients to the training cohort and 340 patients to the validation cohort. The training cohort and the validation cohort matched well. These two cohorts showed no obvious distribution differences for age (<italic>P</italic> = 0.877), sex (<italic>P</italic> = 0.243), race (<italic>P</italic> = 0.376), disease stage (<italic>P</italic> = 0.81), tumor histology (<italic>P</italic> = 0.462), KPS (<italic>P</italic> = 0.195), induction chemotherapy (<italic>P</italic> = 0.228), GTV (<italic>P</italic> = 0.418), MLD (<italic>P</italic> = 0.579), and radiation modality (<italic>P</italic> = 0.633). Distributions of smoking status and total dose showed slight difference, however, as shown in Table <xref ref-type="table" rid="T2">2</xref>, smoking status didn't contribute to the incidence of grade &#x02265; 2 RP (hazard ratio [HR] 0.825, 95% CI 0.532&#x02013;1.279, <italic>P</italic> = 0.39) or grade &#x02265; 3 RP (HR 1.123, 95% CI 0.489&#x02013;2.58, <italic>P</italic> = 0.784). No significant associations were shown between total dose and the risk of grade &#x02265;2 RP (HR 0.799, 95% CI 0.622&#x02013;1.026, <italic>P</italic> = 0.079) or grade &#x02265;3 RP (HR 0.657, 95% CI 0.421&#x02013;1.026, <italic>P</italic> = 0.065), either.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Univariate and multivariate Cox regression analyses to identify clinical predictors of grade &#x02265; 2 and 3 radiation pneumonitis</title></caption><table frame="box" rules="all"><thead><tr><th rowspan="3" align="center" valign="middle" colspan="1">Characteristic</th><th colspan="6" align="center" valign="middle" rowspan="1">grade &#x02265; 2 radiation pneumonitis</th><th colspan="6" align="center" valign="middle" rowspan="1">grade &#x02265;3 radiation pneumonitis</th></tr><tr><th colspan="3" align="center" valign="middle" rowspan="1">Univariate Analysis</th><th colspan="3" align="center" valign="middle" rowspan="1">Multivariate Analysis*</th><th colspan="3" align="center" valign="middle" rowspan="1">Univariate Analysis</th><th colspan="3" align="center" valign="middle" rowspan="1">Multivariate Analysis*</th></tr><tr><th align="left" valign="middle" rowspan="1" colspan="1">HR</th><th align="center" valign="middle" rowspan="1" colspan="1">95% CI</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic></th><th align="center" valign="middle" rowspan="1" colspan="1">HR</th><th align="center" valign="middle" rowspan="1" colspan="1">96% CI</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic></th><th align="center" valign="middle" rowspan="1" colspan="1">HR</th><th align="center" valign="middle" rowspan="1" colspan="1">95% CI</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic></th><th align="center" valign="middle" rowspan="1" colspan="1">HR</th><th align="center" valign="middle" rowspan="1" colspan="1">96% CI</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age (&#x02265; 66 vs. &#x0003c; 66)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.236</td><td align="center" valign="middle" rowspan="1" colspan="1">0.964&#x02013;1.585</td><td align="center" valign="middle" rowspan="1" colspan="1">0.095</td><td align="center" valign="middle" rowspan="1" colspan="1">1.347</td><td align="center" valign="middle" rowspan="1" colspan="1">1.042&#x02013;1.741</td><td align="center" valign="middle" rowspan="1" colspan="1">0.023</td><td align="center" valign="middle" rowspan="1" colspan="1">1.545</td><td align="center" valign="middle" rowspan="1" colspan="1">0.993&#x02013;2.401</td><td align="center" valign="middle" rowspan="1" colspan="1">0.054</td><td align="center" valign="middle" rowspan="1" colspan="1">1.825</td><td align="center" valign="middle" rowspan="1" colspan="1">1.158&#x02013;2.875</td><td align="center" valign="middle" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sex (male vs. female)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.005</td><td align="center" valign="middle" rowspan="1" colspan="1">0.784&#x02013;1.290</td><td align="center" valign="middle" rowspan="1" colspan="1">0.966</td><td align="center" valign="middle" rowspan="1" colspan="1">NI</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.188</td><td align="center" valign="middle" rowspan="1" colspan="1">0.764&#x02013;1.848</td><td align="center" valign="middle" rowspan="1" colspan="1">0.443</td><td align="center" valign="middle" rowspan="1" colspan="1">NI</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Race (black and other vs. white)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.053</td><td align="center" valign="middle" rowspan="1" colspan="1">0.742&#x02013;1.493</td><td align="center" valign="middle" rowspan="1" colspan="1">0.773</td><td align="center" valign="middle" rowspan="1" colspan="1">NI</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.048</td><td align="center" valign="middle" rowspan="1" colspan="1">0.568&#x02013;1.934</td><td align="center" valign="middle" rowspan="1" colspan="1">0.881</td><td align="center" valign="middle" rowspan="1" colspan="1">NI</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Disease stage<break/>(IIIB, IV, recurrence vs. I&#x02013;IIIA)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.010</td><td align="center" valign="middle" rowspan="1" colspan="1">0.782&#x02013;1.303</td><td align="center" valign="middle" rowspan="1" colspan="1">0.941</td><td align="center" valign="middle" rowspan="1" colspan="1">NI</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.779</td><td align="center" valign="middle" rowspan="1" colspan="1">0.499&#x02013;1.217</td><td align="center" valign="middle" rowspan="1" colspan="1">0.273</td><td align="center" valign="middle" rowspan="1" colspan="1">NI</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Histology</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SCC &#x00026; Other vs. Adenocarcinoma</td><td align="center" valign="middle" rowspan="1" colspan="1">0.954</td><td align="center" valign="middle" rowspan="1" colspan="1">0.743&#x02013;1.224</td><td align="center" valign="middle" rowspan="1" colspan="1">0.711</td><td align="center" valign="middle" rowspan="1" colspan="1">NI</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.968</td><td align="center" valign="middle" rowspan="1" colspan="1">0.625&#x02013;1.498</td><td align="center" valign="middle" rowspan="1" colspan="1">0.883</td><td align="center" valign="middle" rowspan="1" colspan="1">NI</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">KPS (&#x02265; 80 vs. &#x0003c; 80)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.771</td><td align="center" valign="middle" rowspan="1" colspan="1">0.554&#x02013;1.075</td><td align="center" valign="middle" rowspan="1" colspan="1">0.125</td><td align="center" valign="middle" rowspan="1" colspan="1">0.820</td><td align="center" valign="middle" rowspan="1" colspan="1">0.584&#x02013;1.153</td><td align="center" valign="middle" rowspan="1" colspan="1">0.254</td><td align="center" valign="middle" rowspan="1" colspan="1">0.510</td><td align="center" valign="middle" rowspan="1" colspan="1">0.305&#x02013;0.852</td><td align="center" valign="middle" rowspan="1" colspan="1">0.01</td><td align="center" valign="middle" rowspan="1" colspan="1">0.552</td><td align="center" valign="middle" rowspan="1" colspan="1">0.325&#x02013;0.936</td><td align="center" valign="middle" rowspan="1" colspan="1">0.027</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Induction chemotherapy (yes vs. no)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.026</td><td align="center" valign="middle" rowspan="1" colspan="1">0.794&#x02013;1.327</td><td align="center" valign="middle" rowspan="1" colspan="1">0.843</td><td align="center" valign="middle" rowspan="1" colspan="1">NI</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.246</td><td align="center" valign="middle" rowspan="1" colspan="1">0.802&#x02013;1.938</td><td align="center" valign="middle" rowspan="1" colspan="1">0.328</td><td align="center" valign="middle" rowspan="1" colspan="1">NI</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Smoking status<break/>(current/former vs. never)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.825</td><td align="center" valign="middle" rowspan="1" colspan="1">0.532&#x02013;1.279</td><td align="center" valign="middle" rowspan="1" colspan="1">0.390</td><td align="center" valign="middle" rowspan="1" colspan="1">NI</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.123</td><td align="center" valign="middle" rowspan="1" colspan="1">0.489&#x02013;2.580</td><td align="center" valign="middle" rowspan="1" colspan="1">0.784</td><td align="center" valign="middle" rowspan="1" colspan="1">NI</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Total dose <break/>(&#x02265; 69.03 vs. &#x0003c; 69.03)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.799</td><td align="center" valign="middle" rowspan="1" colspan="1">0.622&#x02013;1.026</td><td align="center" valign="middle" rowspan="1" colspan="1">0.079</td><td align="center" valign="middle" rowspan="1" colspan="1">NI</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.657</td><td align="center" valign="middle" rowspan="1" colspan="1">0.421&#x02013;1.026</td><td align="center" valign="middle" rowspan="1" colspan="1">0.065</td><td align="center" valign="middle" rowspan="1" colspan="1">NI</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gross tumor volume<break/>(&#x02265; 95.2 cm3 vs. &#x0003c; 95.2 cm3)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.539</td><td align="center" valign="middle" rowspan="1" colspan="1">1.186&#x02013;1.999</td><td align="center" valign="middle" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">NI</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">2.76</td><td align="center" valign="middle" rowspan="1" colspan="1">1.678&#x02013;4.539</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c; 0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">NI</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mean lung dose (&#x02265; 17.9 Gy vs. &#x0003c; 17.9 Gy)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.080</td><td align="center" valign="middle" rowspan="1" colspan="1">1.601&#x02013;2.703</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c; 0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">2.191</td><td align="center" valign="middle" rowspan="1" colspan="1">1.680&#x02013;2.856</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c; 0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">3.922</td><td align="center" valign="middle" rowspan="1" colspan="1">2.318&#x02013;6.639</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c; 0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">4.253</td><td align="center" valign="middle" rowspan="1" colspan="1">2.493&#x02013;7.257</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Radiation modality<break/>(proton vs. 3D&#x02013;CRT + IMRT)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.932</td><td align="center" valign="middle" rowspan="1" colspan="1">0.688&#x02013;1.263</td><td align="center" valign="middle" rowspan="1" colspan="1">0.650</td><td align="center" valign="middle" rowspan="1" colspan="1">NI</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.65</td><td align="center" valign="middle" rowspan="1" colspan="1">0.359&#x02013;1.176</td><td align="center" valign="middle" rowspan="1" colspan="1">0.154</td><td align="center" valign="middle" rowspan="1" colspan="1">0.766</td><td align="center" valign="middle" rowspan="1" colspan="1">0.419&#x02013;1.4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.386</td></tr></tbody></table><table-wrap-foot><p>*Characteristics with a <italic>P</italic> value of &#x0003c;0.05 in the univariate analysis were entered into the multivariate model in a stepwise fashion and were removed if at any point the <italic>P</italic> value was &#x0003e; 0.20.</p><p><italic>Abbreviations</italic>: HR, hazard ratio; CI, confidence interval; NI, not included; KPS, Karnofsky Performance Status score; SCC, squamous cell carcinoma; 3D&#x02013;CRT, 3&#x02013;dimensional conformal (photon) radiation therapy; IMRT, intensity&#x02013;modulated (photon) radiation therapy</p></table-wrap-foot></table-wrap></sec><sec id="s2_2"><title>Clinical predictors of RP</title><p>The ability of characteristics shown in Table <xref ref-type="table" rid="T1">1</xref> to predict the incidence of RP of grade &#x0003c; 2 versus &#x02265; 2 or grade &#x0003c; 3 versus &#x02265; 3 were then evaluated in a stepwise fashion as follows. Variables found in univariate Cox regression analysis with <italic>P</italic> values of &#x0003c; 0.05 were entered into the multivariate analysis, and then removed if the <italic>P value</italic> was &#x0003e; 0.20. Significant associations were found in univariate analysis between the incidence of grade &#x02265; 2 RP and GTV (HR 1.539, 95% confidence interval [CI] 1.186&#x02013;1.999, <italic>P</italic> = 0.001) or MLD (HR 2.080, 95% CI 1.601&#x02013;2.703, <italic>P</italic> &#x0003c; 0.001) (Table <xref ref-type="table" rid="T2">2</xref>). Because of the correlation between GTV and MLD, only MLD (the variable with larger HR and lower <italic>P value</italic>) was entered into the multivariate analysis. Multivariate analysis revealed that the risk of grade &#x02265; 2 RP was increased among patients who were &#x02265; 66 years old (HR 1.347, 95% CI 1.042&#x02013;1.741, <italic>P</italic> = 0.023) and those whose MLD &#x02265; 17.9 Gy (HR 2.191, 95% CI 1.680&#x02013;2.856, <italic>P</italic> &#x0003c; 0.001) (Table <xref ref-type="table" rid="T2">2</xref>). Similar results were observed for the risk of grade &#x02265; 3 RP. Older patients or patients with higher MLD had greater risk of developing grade &#x02265; 3 RP. Besides, patients with higher KPS had the lower risk of grade &#x02265; 3 RP (HR 0.552, 95% CI 0.325&#x02013;0.936, <italic>P</italic> = 0.027). In summary, these findings validated the already established role of MLD in the risk of RP.</p></sec><sec id="s2_3"><title>Associations between SNPs in <italic>BMPs</italic> and RP</title><p>Next, we evaluated whether the <italic>BMP</italic> SNPs we genotyped (distribution shown in <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 2</xref>) were associated with risks of grade &#x02265; 2 or grade &#x02265; 3 RP. The univariate analysis showed that <italic>BMP2</italic> rs235768 AT/TT genotypes were strongly associated with increased risk of grade &#x02265; 2 RP in the training cohort (HR 2.455, 95% CI 1.243&#x02013;4.847, <italic>P</italic> = 0.010), validation cohort (HR 1.92, 95% CI 1.118&#x02013;3.298, <italic>P</italic> = 0.018), and the pooled analysis (HR 2.090, 95% CI 1.370&#x02013;3.187, <italic>P</italic> = 0.001) (Table <xref ref-type="table" rid="T3">3</xref>). Similar results were also found in the multivariate analysis (training cohort: HR 2.186, 95% CI 1.103&#x02013;4.333, <italic>P</italic> = 0.025; validation cohort: HR 1.884, 95% CI 1.093&#x02013;3.246, <italic>P</italic> = 0.023; the pooled analysis: HR 1.866, 95% CI 1.221&#x02013;2.820, <italic>P</italic> = 0.004) (Table <xref ref-type="table" rid="T4">4</xref>; Figure <xref ref-type="fig" rid="F1">1B</xref>). For <italic>BMP2</italic> rs1980499, the univariate analysis of the training cohort suggested that genotypes CT/TT were associated with increased risk of grade &#x02265; 2 RP (HR 1.648, 95% CI 1.028&#x02013;2.642, <italic>P</italic> = 0.038), while these results were not validated by the validation cohort (HR 1.461, 95% CI 0.946&#x02013;2.256, <italic>P</italic> = 0.088). However, the pooled analysis still showed significant associations (HR 1.532, 95% CI 1.113&#x02013;2.108, <italic>P</italic> = 0.009) (Table <xref ref-type="table" rid="T3">3</xref>). The multivariate analysis in the pooled cohort also showed that <italic>BMP2</italic> rs1980499 genotypes CT/TT were associated with increased risk of grade &#x02265; 2 RP (HR 1.403, 95% CI 1.014&#x02013;1.941, <italic>P</italic> = 0.041) (Table <xref ref-type="table" rid="T4">4</xref>; Figure <xref ref-type="fig" rid="F1">1A</xref>).</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Univariate analysis of associations between single-nucleotide polymorphisms (SNPs) and grade &#x02265; 2 radiation pneumonitis</title></caption><table frame="box" rules="all"><thead><tr><th rowspan="2" align="left" valign="middle" colspan="1">SNPs</th><th colspan="3" align="center" valign="middle" rowspan="1">Training Cohort</th><th colspan="3" align="center" valign="middle" rowspan="1">Validation Cohort</th><th colspan="3" align="center" valign="middle" rowspan="1">Pooled analysis</th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">HR</th><th align="center" valign="middle" rowspan="1" colspan="1">95% CI</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic></th><th align="center" valign="middle" rowspan="1" colspan="1">HR</th><th align="center" valign="middle" rowspan="1" colspan="1">95% CI</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic></th><th align="center" valign="middle" rowspan="1" colspan="1">HR</th><th align="center" valign="middle" rowspan="1" colspan="1">95% CI</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold><italic>BMP2</italic></bold></td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs170986 (CA/CC vs. AA)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">0.442</td><td align="center" valign="middle" rowspan="1" colspan="1">0.18&#x02013;1.082</td><td align="center" valign="middle" rowspan="1" colspan="1">0.074</td><td align="center" valign="middle" rowspan="1" colspan="1">2.073</td><td align="center" valign="middle" rowspan="1" colspan="1">0.659&#x02013;6.523</td><td align="center" valign="middle" rowspan="1" colspan="1">0.212</td><td align="center" valign="middle" rowspan="1" colspan="1">1.038</td><td align="center" valign="middle" rowspan="1" colspan="1">0.513&#x02013;2.101</td><td align="center" valign="middle" rowspan="1" colspan="1">0.917</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs1979855 (AG/AA vs. GG)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">0.522</td><td align="center" valign="middle" rowspan="1" colspan="1">0.165&#x02013;1.651</td><td align="center" valign="middle" rowspan="1" colspan="1">0.268</td><td align="center" valign="middle" rowspan="1" colspan="1">1.853</td><td align="center" valign="middle" rowspan="1" colspan="1">0.458&#x02013;7.495</td><td align="center" valign="middle" rowspan="1" colspan="1">0.387</td><td align="center" valign="middle" rowspan="1" colspan="1">1.049</td><td align="center" valign="middle" rowspan="1" colspan="1">0.432&#x02013;2.545</td><td align="center" valign="middle" rowspan="1" colspan="1">0.916</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs1980499 (CT/TT vs. CC)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">1.648</td><td align="center" valign="middle" rowspan="1" colspan="1">1.028&#x02013;2.642</td><td align="center" valign="middle" rowspan="1" colspan="1">0.038</td><td align="center" valign="middle" rowspan="1" colspan="1">1.461</td><td align="center" valign="middle" rowspan="1" colspan="1">0.946&#x02013;2.256</td><td align="center" valign="middle" rowspan="1" colspan="1">0.088</td><td align="center" valign="middle" rowspan="1" colspan="1">1.532</td><td align="center" valign="middle" rowspan="1" colspan="1">1.113&#x02013;2.108</td><td align="center" valign="middle" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs235768 (AT/TT vs. AA)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">2.455</td><td align="center" valign="middle" rowspan="1" colspan="1">1.243&#x02013;4.847</td><td align="center" valign="middle" rowspan="1" colspan="1">0.010</td><td align="center" valign="middle" rowspan="1" colspan="1">1.920</td><td align="center" valign="middle" rowspan="1" colspan="1">1.118&#x02013;3.298</td><td align="center" valign="middle" rowspan="1" colspan="1">0.018</td><td align="center" valign="middle" rowspan="1" colspan="1">2.090</td><td align="center" valign="middle" rowspan="1" colspan="1">1.370&#x02013;3.187</td><td align="center" valign="middle" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs3178250 (CT/TT vs. CC)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">0.364</td><td align="center" valign="middle" rowspan="1" colspan="1">0.177&#x02013;0.748</td><td align="center" valign="middle" rowspan="1" colspan="1">0.006</td><td align="center" valign="middle" rowspan="1" colspan="1">0.954</td><td align="center" valign="middle" rowspan="1" colspan="1">0.303&#x02013;3.003</td><td align="center" valign="middle" rowspan="1" colspan="1">0.936</td><td align="center" valign="middle" rowspan="1" colspan="1">0.529</td><td align="center" valign="middle" rowspan="1" colspan="1">0.288&#x02013;0.969</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold><italic>BMP4</italic></bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs17563 (AG/GG vs. AA)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">0.844</td><td align="center" valign="middle" rowspan="1" colspan="1">0.563&#x02013;1.266</td><td align="center" valign="middle" rowspan="1" colspan="1">0.413</td><td align="center" valign="middle" rowspan="1" colspan="1">1.280</td><td align="center" valign="middle" rowspan="1" colspan="1">0.843&#x02013;1.942</td><td align="center" valign="middle" rowspan="1" colspan="1">0.246</td><td align="center" valign="middle" rowspan="1" colspan="1">1.047</td><td align="center" valign="middle" rowspan="1" colspan="1">0.783&#x02013;1.400</td><td align="center" valign="middle" rowspan="1" colspan="1">0.756</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs4898820 (GT/TT vs. GG)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">1.198</td><td align="center" valign="middle" rowspan="1" colspan="1">0.739&#x02013;1.940</td><td align="center" valign="middle" rowspan="1" colspan="1">0.464</td><td align="center" valign="middle" rowspan="1" colspan="1">0.933</td><td align="center" valign="middle" rowspan="1" colspan="1">0.601&#x02013;1.448</td><td align="center" valign="middle" rowspan="1" colspan="1">0.757</td><td align="center" valign="middle" rowspan="1" colspan="1">1.062</td><td align="center" valign="middle" rowspan="1" colspan="1">0.768&#x02013;1.469</td><td align="center" valign="middle" rowspan="1" colspan="1">0.716</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs762642 (AC/CC vs. AA)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">1.196</td><td align="center" valign="middle" rowspan="1" colspan="1">0.705&#x02013;2.031</td><td align="center" valign="middle" rowspan="1" colspan="1">0.507</td><td align="center" valign="middle" rowspan="1" colspan="1">1.025</td><td align="center" valign="middle" rowspan="1" colspan="1">0.614&#x02013;1.712</td><td align="center" valign="middle" rowspan="1" colspan="1">0.925</td><td align="center" valign="middle" rowspan="1" colspan="1">1.129</td><td align="center" valign="middle" rowspan="1" colspan="1">0.781&#x02013;1.632</td><td align="center" valign="middle" rowspan="1" colspan="1">0.519</td></tr></tbody></table><table-wrap-foot><p>Abbreviation: HR, hazard ratio; CI, confidence interval.</p></table-wrap-foot></table-wrap><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><title>Multivariate analysis of associations between single-nucleotide polymorphisms (SNPs) and grade &#x02265; 2 radiation pneumonitis</title></caption><table frame="box" rules="all"><thead><tr><th rowspan="2" align="left" valign="middle" colspan="1">SNPs</th><th colspan="3" align="center" valign="middle" rowspan="1">Training Cohort</th><th colspan="3" align="center" valign="middle" rowspan="1">Validation Cohort</th><th colspan="3" align="center" valign="middle" rowspan="1">Pooled analysis</th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">HR</th><th align="center" valign="middle" rowspan="1" colspan="1">95% CI</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic></th><th align="center" valign="middle" rowspan="1" colspan="1">HR</th><th align="center" valign="middle" rowspan="1" colspan="1">95% CI</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic></th><th align="center" valign="middle" rowspan="1" colspan="1">HR</th><th align="center" valign="middle" rowspan="1" colspan="1">95% CI</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><bold><italic>BMP2</italic></bold></td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs170986 (CA/CC vs. AA)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">0.442</td><td align="center" valign="middle" rowspan="1" colspan="1">0.179&#x02013;1.093</td><td align="center" valign="middle" rowspan="1" colspan="1">0.077</td><td align="center" valign="middle" rowspan="1" colspan="1">1.666</td><td align="center" valign="middle" rowspan="1" colspan="1">0.522&#x02013;5.319</td><td align="center" valign="middle" rowspan="1" colspan="1">0.389</td><td align="center" valign="middle" rowspan="1" colspan="1">0.921</td><td align="center" valign="middle" rowspan="1" colspan="1">0.451&#x02013;1.882</td><td align="center" valign="middle" rowspan="1" colspan="1">0.822</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs1979855 (AG/AA vs. GG)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">0.704</td><td align="center" valign="middle" rowspan="1" colspan="1">0.221&#x02013;2.244</td><td align="center" valign="middle" rowspan="1" colspan="1">0.553</td><td align="center" valign="middle" rowspan="1" colspan="1">1.873</td><td align="center" valign="middle" rowspan="1" colspan="1">0.462&#x02013;7.59</td><td align="center" valign="middle" rowspan="1" colspan="1">0.379</td><td align="center" valign="middle" rowspan="1" colspan="1">1.167</td><td align="center" valign="middle" rowspan="1" colspan="1">0.480&#x02013;2.837</td><td align="center" valign="middle" rowspan="1" colspan="1">0.734</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs1980499 (CT/TT vs. CC)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">1.557</td><td align="center" valign="middle" rowspan="1" colspan="1">0.957&#x02013;2.533</td><td align="center" valign="middle" rowspan="1" colspan="1">0.075</td><td align="center" valign="middle" rowspan="1" colspan="1">1.457</td><td align="center" valign="middle" rowspan="1" colspan="1">0.937&#x02013;2.265</td><td align="center" valign="middle" rowspan="1" colspan="1">0.095</td><td align="center" valign="middle" rowspan="1" colspan="1">1.403</td><td align="center" valign="middle" rowspan="1" colspan="1">1.014&#x02013;1.941</td><td align="center" valign="middle" rowspan="1" colspan="1">0.041</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs235768 (AT/TT vs. AA)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">2.186</td><td align="center" valign="middle" rowspan="1" colspan="1">1.103&#x02013;4.333</td><td align="center" valign="middle" rowspan="1" colspan="1">0.025</td><td align="center" valign="middle" rowspan="1" colspan="1">1.884</td><td align="center" valign="middle" rowspan="1" colspan="1">1.093&#x02013;3.246</td><td align="center" valign="middle" rowspan="1" colspan="1">0.023</td><td align="center" valign="middle" rowspan="1" colspan="1">1.866</td><td align="center" valign="middle" rowspan="1" colspan="1">1.221&#x02013;2.820</td><td align="center" valign="middle" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs3178250 (CT/TT vs. CC)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">0.521</td><td align="center" valign="middle" rowspan="1" colspan="1">0.251&#x02013;1.081</td><td align="center" valign="middle" rowspan="1" colspan="1">0.080</td><td align="center" valign="middle" rowspan="1" colspan="1">1.107</td><td align="center" valign="middle" rowspan="1" colspan="1">0.349&#x02013;3.51</td><td align="center" valign="middle" rowspan="1" colspan="1">0.863</td><td align="center" valign="middle" rowspan="1" colspan="1">0.667</td><td align="center" valign="middle" rowspan="1" colspan="1">0.362&#x02013;1.230</td><td align="center" valign="middle" rowspan="1" colspan="1">0.194</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><bold><italic>BMP4</italic></bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs17563 (AG/GG vs. AA)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">0.885</td><td align="center" valign="middle" rowspan="1" colspan="1">0.584&#x02013;1.343</td><td align="center" valign="middle" rowspan="1" colspan="1">0.567</td><td align="center" valign="middle" rowspan="1" colspan="1">1.351</td><td align="center" valign="middle" rowspan="1" colspan="1">0.888&#x02013;2.055</td><td align="center" valign="middle" rowspan="1" colspan="1">0.16</td><td align="center" valign="middle" rowspan="1" colspan="1">1.115</td><td align="center" valign="middle" rowspan="1" colspan="1">0.830&#x02013;1.499</td><td align="center" valign="middle" rowspan="1" colspan="1">0.470</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs4898820 (GT/TT vs. GG)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">1.347</td><td align="center" valign="middle" rowspan="1" colspan="1">0.811&#x02013;2.236</td><td align="center" valign="middle" rowspan="1" colspan="1">0.25</td><td align="center" valign="middle" rowspan="1" colspan="1">0.909</td><td align="center" valign="middle" rowspan="1" colspan="1">0.584&#x02013;1.415</td><td align="center" valign="middle" rowspan="1" colspan="1">0.673</td><td align="center" valign="middle" rowspan="1" colspan="1">1.115</td><td align="center" valign="middle" rowspan="1" colspan="1">0.800&#x02013;1.555</td><td align="center" valign="middle" rowspan="1" colspan="1">0.521</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs762642 (AC/CC vs. AA)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">1.303</td><td align="center" valign="middle" rowspan="1" colspan="1">0.753&#x02013;2.254</td><td align="center" valign="middle" rowspan="1" colspan="1">0.345</td><td align="center" valign="middle" rowspan="1" colspan="1">1.006</td><td align="center" valign="middle" rowspan="1" colspan="1">0.601&#x02013;1.685</td><td align="center" valign="middle" rowspan="1" colspan="1">0.982</td><td align="center" valign="middle" rowspan="1" colspan="1">1.156</td><td align="center" valign="middle" rowspan="1" colspan="1">0.794&#x02013;1.682</td><td align="center" valign="middle" rowspan="1" colspan="1">0.449</td></tr></tbody></table><table-wrap-foot><p>Note: Age, Karnofsky Performance Status score, mean lung dose were used as covariates in multivariate analysis.</p><p>Abbreviation: HR, hazard ratio; CI, confidence interval.</p></table-wrap-foot></table-wrap><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Cumulative probability of grade &#x02265; 2 or 3 radiation pneumonitis (RP) in 664 patients with non-small cell lung cancer according to <italic>BMP2</italic> genotypes</title><p>(<bold>A</bold>) Effects of <italic>BMP2</italic> rs1980499 genotypes CT and TT versus CC on RP grade &#x02265; 2. (<bold>B</bold>) Effects of <italic>BMP2</italic> rs235768 genotypes AT and TT versus AA on RP grade &#x02265; 2. (<bold>C</bold>) Combined effects of <italic>BMP2</italic> rs1980499 genotypes and MLD on the risk of RP grade &#x02265; 2. (<bold>D</bold>) Combined effects of <italic>BMP2</italic> rs235768 genotypes and MLD on the risk of RP grade &#x02265; 2. (<bold>E</bold>) Effects of <italic>BMP2</italic> rs3178250 genotypes CT and TT versus CC on the risk of RP grade &#x02265; 3. The cut-off value for higher and lower MLD is 17.9 Gy (the median dose of MLD).</p></caption><graphic xlink:href="oncotarget-08-43080-g001"/></fig><p>The training cohort showed that <italic>BMP2</italic> rs3178250 genotypes CT/TT were obviously associated with the risk of grade &#x02265; 3 RP both in the univariate analysis (HR 0.272, 95% CI 0.108&#x02013;0.687, <italic>P</italic> = 0.006) and multivariate analysis (HR 0.378, 95% CI 0.148&#x02013;0.936, <italic>P</italic> = 0.041) (Table <xref ref-type="table" rid="T5">5</xref>; Table <xref ref-type="table" rid="T6">6</xref>). However, the validation cohort did not validate these results, but the pooled analysis still showed the significant associations in uni- (HR 0.303, 95% CI 0.132&#x02013;0.698, <italic>P</italic> = 0.005) and multivariate analysis (HR 0.406, 95% CI 0.175&#x02013;0.942, <italic>P</italic> = 0.036) (Table <xref ref-type="table" rid="T6">6</xref>; Figure <xref ref-type="fig" rid="F1">1E</xref>).</p><table-wrap id="T5" orientation="portrait" position="float"><label>Table 5</label><caption><title>Univariate analysis of associations between single-nucleotide polymorphisms (SNPs) and grade &#x02265; 3 radiation pneumonitis</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">SNPs</th><th colspan="3" align="center" valign="middle" rowspan="1">Training Cohort</th><th colspan="3" align="center" valign="middle" rowspan="1">Validation Cohort</th><th colspan="3" align="center" valign="middle" rowspan="1">Pooled analysis</th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">BMP2</th><th align="center" valign="middle" rowspan="1" colspan="1">HR</th><th align="center" valign="middle" rowspan="1" colspan="1">95% CI</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic></th><th align="center" valign="middle" rowspan="1" colspan="1">HR</th><th align="center" valign="middle" rowspan="1" colspan="1">95% CI</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic></th><th align="center" valign="middle" rowspan="1" colspan="1">HR</th><th align="center" valign="middle" rowspan="1" colspan="1">95% CI</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs170986 (CA/CC vs. AA)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">0.345</td><td align="center" valign="middle" rowspan="1" colspan="1">0.107&#x02013;1.11</td><td align="center" valign="middle" rowspan="1" colspan="1">0.074</td><td align="center" valign="middle" rowspan="1" colspan="1">1.484</td><td align="center" valign="middle" rowspan="1" colspan="1">0.202&#x02013;10.905</td><td align="center" valign="middle" rowspan="1" colspan="1">0.698</td><td align="center" valign="middle" rowspan="1" colspan="1">0.691</td><td align="center" valign="middle" rowspan="1" colspan="1">0.253&#x02013;1.891</td><td align="center" valign="middle" rowspan="1" colspan="1">0.472</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs1979855 (AG/AA vs. GG)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">0.870</td><td align="center" valign="middle" rowspan="1" colspan="1">0.120&#x02013;6.316</td><td align="center" valign="middle" rowspan="1" colspan="1">0.890</td><td align="center" valign="middle" rowspan="1" colspan="1">0.680</td><td align="center" valign="middle" rowspan="1" colspan="1">0.092&#x02013;5.005</td><td align="center" valign="middle" rowspan="1" colspan="1">0.705</td><td align="center" valign="middle" rowspan="1" colspan="1">0.818</td><td align="center" valign="middle" rowspan="1" colspan="1">0.201&#x02013;3.335</td><td align="center" valign="middle" rowspan="1" colspan="1">0.779</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs1980499 (CT/TT vs. CC)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">1.640</td><td align="center" valign="middle" rowspan="1" colspan="1">0.768&#x02013;3.505</td><td align="center" valign="middle" rowspan="1" colspan="1">0.201</td><td align="center" valign="middle" rowspan="1" colspan="1">1.047</td><td align="center" valign="middle" rowspan="1" colspan="1">0.443&#x02013;2.477</td><td align="center" valign="middle" rowspan="1" colspan="1">1.047</td><td align="center" valign="middle" rowspan="1" colspan="1">1.390</td><td align="center" valign="middle" rowspan="1" colspan="1">0.790&#x02013;2.448</td><td align="center" valign="middle" rowspan="1" colspan="1">0.254</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs235768 (AT/TT vs. AA)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">1.957</td><td align="center" valign="middle" rowspan="1" colspan="1">0.703&#x02013;5.449</td><td align="center" valign="middle" rowspan="1" colspan="1">0.199</td><td align="center" valign="middle" rowspan="1" colspan="1">1.104</td><td align="center" valign="middle" rowspan="1" colspan="1">0.421&#x02013;2.893</td><td align="center" valign="middle" rowspan="1" colspan="1">0.841</td><td align="center" valign="middle" rowspan="1" colspan="1">1.534</td><td align="center" valign="middle" rowspan="1" colspan="1">0.765&#x02013;3.075</td><td align="center" valign="middle" rowspan="1" colspan="1">0.228</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs3178250 (CT/TT vs. CC)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">0.272</td><td align="center" valign="middle" rowspan="1" colspan="1">0.108&#x02013;0.687</td><td align="center" valign="middle" rowspan="1" colspan="1">0.006</td><td align="center" valign="middle" rowspan="1" colspan="1">0.524</td><td align="center" valign="middle" rowspan="1" colspan="1">0.071&#x02013;3.870</td><td align="center" valign="middle" rowspan="1" colspan="1">0.524</td><td align="center" valign="middle" rowspan="1" colspan="1">0.303</td><td align="center" valign="middle" rowspan="1" colspan="1">0.132&#x02013;0.698</td><td align="center" valign="middle" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold><italic>BMP4</italic></bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs17563 (AG/GG vs. AA)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">0.806</td><td align="center" valign="middle" rowspan="1" colspan="1">0.434&#x02013;1.499</td><td align="center" valign="middle" rowspan="1" colspan="1">0.496</td><td align="center" valign="middle" rowspan="1" colspan="1">2.452</td><td align="center" valign="middle" rowspan="1" colspan="1">0.853&#x02013;7.048</td><td align="center" valign="middle" rowspan="1" colspan="1">0.096</td><td align="center" valign="middle" rowspan="1" colspan="1">1.182</td><td align="center" valign="middle" rowspan="1" colspan="1">0.698&#x02013;2.001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.535</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs4898820 (GT/TT vs. GG)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">1.761</td><td align="center" valign="middle" rowspan="1" colspan="1">0.748&#x02013;4.148</td><td align="center" valign="middle" rowspan="1" colspan="1">0.195</td><td align="center" valign="middle" rowspan="1" colspan="1">0.926</td><td align="center" valign="middle" rowspan="1" colspan="1">0.377&#x02013;2.276</td><td align="center" valign="middle" rowspan="1" colspan="1">0.926</td><td align="center" valign="middle" rowspan="1" colspan="1">0.332</td><td align="center" valign="middle" rowspan="1" colspan="1">1.357&#x02013;2.514</td><td align="center" valign="middle" rowspan="1" colspan="1">0.332</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs762642 (AC/CC vs. AA)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">2.176</td><td align="center" valign="middle" rowspan="1" colspan="1">0.780&#x02013;6.068</td><td align="center" valign="middle" rowspan="1" colspan="1">0.137</td><td align="center" valign="middle" rowspan="1" colspan="1">1.073</td><td align="center" valign="middle" rowspan="1" colspan="1">0.373&#x02013;3.084</td><td align="center" valign="middle" rowspan="1" colspan="1">0.896</td><td align="center" valign="middle" rowspan="1" colspan="1">1.614</td><td align="center" valign="middle" rowspan="1" colspan="1">0.775&#x02013;3.360</td><td align="center" valign="middle" rowspan="1" colspan="1">0.201</td></tr></tbody></table><table-wrap-foot><p>Abbreviation: HR, hazard ratio; CI, confidence interval.</p></table-wrap-foot></table-wrap><table-wrap id="T6" orientation="portrait" position="float"><label>Table 6</label><caption><title>Multivariate analysis of associations between single-nucleotide polymorphisms (SNPs) and grade &#x02265; 3 radiation pneumonitis</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">SNPs</th><th colspan="3" align="center" valign="middle" rowspan="1">Training Cohort</th><th colspan="3" align="center" valign="middle" rowspan="1">Validation Cohort</th><th colspan="3" align="center" valign="middle" rowspan="1">Pooled analysis</th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1"><italic>BMP2</italic></th><th align="center" valign="middle" rowspan="1" colspan="1">HR</th><th align="center" valign="middle" rowspan="1" colspan="1">95% CI</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic></th><th align="center" valign="middle" rowspan="1" colspan="1">HR</th><th align="center" valign="middle" rowspan="1" colspan="1">95% CI</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic></th><th align="center" valign="middle" rowspan="1" colspan="1">HR</th><th align="center" valign="middle" rowspan="1" colspan="1">95% CI</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs170986 (CA/CC vs. AA)</bold></td><td align="left" valign="middle" rowspan="1" colspan="1">0.393</td><td align="left" valign="middle" rowspan="1" colspan="1">0.120&#x02013;1.282</td><td align="left" valign="middle" rowspan="1" colspan="1">0.122</td><td align="left" valign="middle" rowspan="1" colspan="1">0.945</td><td align="left" valign="middle" rowspan="1" colspan="1">0.124&#x02013;7.196</td><td align="left" valign="middle" rowspan="1" colspan="1">0.957</td><td align="left" valign="middle" rowspan="1" colspan="1">0.579</td><td align="left" valign="middle" rowspan="1" colspan="1">0.208&#x02013;1.613</td><td align="left" valign="middle" rowspan="1" colspan="1">0.296</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs1979855 (AG/AA vs. GG)</bold></td><td align="left" valign="middle" rowspan="1" colspan="1">1.157</td><td align="left" valign="middle" rowspan="1" colspan="1">0.158&#x02013;8.486</td><td align="left" valign="middle" rowspan="1" colspan="1">0.886</td><td align="left" valign="middle" rowspan="1" colspan="1">0.665</td><td align="left" valign="middle" rowspan="1" colspan="1">0.089&#x02013;4.953</td><td align="left" valign="middle" rowspan="1" colspan="1">0.690</td><td align="left" valign="middle" rowspan="1" colspan="1">0.959</td><td align="left" valign="middle" rowspan="1" colspan="1">0.234&#x02013;3.933</td><td align="left" valign="middle" rowspan="1" colspan="1">0.954</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs1980499 (CT/TT vs. CC)</bold></td><td align="left" valign="middle" rowspan="1" colspan="1">1.454</td><td align="left" valign="middle" rowspan="1" colspan="1">0.675&#x02013;3.132</td><td align="left" valign="middle" rowspan="1" colspan="1">0.339</td><td align="left" valign="middle" rowspan="1" colspan="1">1.028</td><td align="left" valign="middle" rowspan="1" colspan="1">0.432&#x02013;2.447</td><td align="left" valign="middle" rowspan="1" colspan="1">0.950</td><td align="left" valign="middle" rowspan="1" colspan="1">1.216</td><td align="left" valign="middle" rowspan="1" colspan="1">0.688&#x02013;2.147</td><td align="left" valign="middle" rowspan="1" colspan="1">0.501</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs235768 (AT/TT vs. AA)</bold></td><td align="left" valign="middle" rowspan="1" colspan="1">1.655</td><td align="left" valign="middle" rowspan="1" colspan="1">0.591&#x02013;4.632</td><td align="left" valign="middle" rowspan="1" colspan="1">0.337</td><td align="left" valign="middle" rowspan="1" colspan="1">1.027</td><td align="left" valign="middle" rowspan="1" colspan="1">0.390&#x02013;2.704</td><td align="left" valign="middle" rowspan="1" colspan="1">0.956</td><td align="left" valign="middle" rowspan="1" colspan="1">1.307</td><td align="left" valign="middle" rowspan="1" colspan="1">0.650&#x02013;2.626</td><td align="left" valign="middle" rowspan="1" colspan="1">0.452</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">rs3178250 (CT/TT vs. CC)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.378</td><td align="left" valign="middle" rowspan="1" colspan="1">0.148&#x02013;0.936</td><td align="left" valign="middle" rowspan="1" colspan="1">0.041</td><td align="left" valign="middle" rowspan="1" colspan="1">0.701</td><td align="left" valign="middle" rowspan="1" colspan="1">0.093&#x02013;5.254</td><td align="left" valign="middle" rowspan="1" colspan="1">0.729</td><td align="left" valign="middle" rowspan="1" colspan="1">0.406</td><td align="left" valign="middle" rowspan="1" colspan="1">0.175&#x02013;0.942</td><td align="left" valign="middle" rowspan="1" colspan="1">0.036</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold><italic>BMP4</italic></bold></td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs17563 (AG/GG vs. AA)</bold></td><td align="left" valign="middle" rowspan="1" colspan="1">0.809</td><td align="left" valign="middle" rowspan="1" colspan="1">0.430&#x02013;1.520</td><td align="left" valign="middle" rowspan="1" colspan="1">0.509</td><td align="left" valign="middle" rowspan="1" colspan="1">2.791</td><td align="left" valign="middle" rowspan="1" colspan="1">0.968&#x02013;8.050</td><td align="left" valign="middle" rowspan="1" colspan="1">0.057</td><td align="left" valign="middle" rowspan="1" colspan="1">1.275</td><td align="left" valign="middle" rowspan="1" colspan="1">0.751&#x02013;2.168</td><td align="left" valign="middle" rowspan="1" colspan="1">0.369</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs4898820 (GT/TT vs. GG)</bold></td><td align="left" valign="middle" rowspan="1" colspan="1">1.763</td><td align="left" valign="middle" rowspan="1" colspan="1">0.746&#x02013;4.168</td><td align="left" valign="middle" rowspan="1" colspan="1">0.196</td><td align="left" valign="middle" rowspan="1" colspan="1">0.957</td><td align="left" valign="middle" rowspan="1" colspan="1">0.386&#x02013;2.370</td><td align="left" valign="middle" rowspan="1" colspan="1">0.924</td><td align="left" valign="middle" rowspan="1" colspan="1">1.414</td><td align="left" valign="middle" rowspan="1" colspan="1">0.761&#x02013;2.627</td><td align="left" valign="middle" rowspan="1" colspan="1">0.273</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>rs762642 (AC/CC vs. AA)</bold></td><td align="left" valign="middle" rowspan="1" colspan="1">2.139</td><td align="left" valign="middle" rowspan="1" colspan="1">0.764&#x02013;5.987</td><td align="left" valign="middle" rowspan="1" colspan="1">0.148</td><td align="left" valign="middle" rowspan="1" colspan="1">1.080</td><td align="left" valign="middle" rowspan="1" colspan="1">0.374&#x02013;3.121</td><td align="left" valign="middle" rowspan="1" colspan="1">0.887</td><td align="left" valign="middle" rowspan="1" colspan="1">1.638</td><td align="left" valign="middle" rowspan="1" colspan="1">0.785&#x02013;3.418</td><td align="left" valign="middle" rowspan="1" colspan="1">0.188</td></tr></tbody></table><table-wrap-foot><p>Note: Age, Karnofsky Performance Status score, mean lung dose were used as covariates in multivariate analysis.</p><p>Abbreviation: HR, hazard ratio; CI, confidence interval.</p></table-wrap-foot></table-wrap></sec><sec id="s2_4"><title>Incorporating SNPs into an clinical model</title><p>As shown in Figure <xref ref-type="fig" rid="F1">1C and 1D</xref>, the risk of developing RP &#x02265;2 RP was highest in patients with <italic>BMP2</italic> rs1980499 gentoypes CT/TT and higher MLD or <italic>BMP2</italic> rs235768 AT/TT genotypes and higher MLD. Finally, we investigated if the two grade &#x02265; 2 RP associated <italic>BMP2</italic> SNPs (rs235768 and rs1980499) could improve the prediction of the clinical model consisted of age, KPS, and MLD [<xref rid="R4" ref-type="bibr">4</xref>]. To do so, we calculated Harrell's <italic>C</italic> to compare the predictive power of the models with or without the SNPs. The Harrell's <italic>C</italic> of the model without the SNPs was 0.6117, and it significantly increased to 0.6235 after the SNPs had been added (<italic>P</italic> = 0.0105). Receiver operating characteristics curve was also used to validate our results. As shown in Figure <xref ref-type="fig" rid="F2">2</xref>, a model containing MLD and rs235768 exhibited an AUC of 0.617, which was greater than model with MLD alone (AUC = 0.596). The difference between areas was also significant (95% CI: 0.00737&#x02013;0.0346, <italic>P</italic> = 0.0025).</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Receiver operating characteristics shown for models including only MLD (black line) or both MLD and rs235768 (dashed line) for grade &#x02265; 2 radiation pneumonitis (RP) with corresponding areas under curves (AUCs)</title></caption><graphic xlink:href="oncotarget-08-43080-g002"/></fig></sec></sec><sec id="s3"><title>DISCUSSION</title><p>To the best of our knowledge, this is the first study to investigate potential associations between SNPs in <italic>BMPs</italic> and the risk of RP. We found that <italic>BMP2</italic> SNPs rs235768 and rs1980499 were associated with risk of grade &#x02265; 2 RP; and rs3178250 was associated with the risk of grade &#x02265; 3 RP in patients with NSCLC after definitive radiotherapy. However, no association was found between <italic>BMP4</italic> SNPs and RP. Furthermore, we validated that higher MLD was a risk factor for RP and incorporating the SNPs (rs235768 and rs1980499) into an existing MLD-based model could more effectively predict the risk of RP.</p><p>Our findings also make sense from a biological standpoint. Like the general inflammation process, RP is a severe acute inflammatory response to radiation, followed by tissue repair and pulmonary fibrosis [<xref rid="R14" ref-type="bibr">14</xref>]. <italic>BMP2</italic> has complicated roles in this process, having been found to increase both during airway inflammation [<xref rid="R15" ref-type="bibr">15</xref>] and after exposure to pro-inflammatory stimuli such as TNF&#x003b1;. Early in the inflammatory process, increased expression of <italic>BMP2</italic> could have pro-inflammatory effects by inducing endothelial dysfunction, oxidative stress, and endothelial activation [<xref rid="R10" ref-type="bibr">10</xref>]. In the consequent tissue repair process, <italic>BMP2</italic> could have a novel role as a fibrosis-antagonizing cytokine through inhibiting TGF&#x003b2;1 signaling [<xref rid="R16" ref-type="bibr">16</xref>, <xref rid="R17" ref-type="bibr">17</xref>]. Therefore aberrant expression of <italic>BMP2</italic> could aggravate inflammation, induce more severe toxicity, or attenuate normal pulmonary tissue repair during radiation-induced lung injury. <italic>BMP2</italic> rs235768 is a non-synonymous mutation located in the coding area and may affect the protein product. Indeed, one study revealed that <italic>BMP2</italic> rs235768 could contribute to higher expression of <italic>BMP2 in vitro</italic> [<xref rid="R18" ref-type="bibr">18</xref>]. These mechanisms could explain our finding that the BMP2 rs235768 AT/TT genotypes could increase the risk of RP. <italic>BMP2</italic> rs1980499 is located within the transcriptional factor binding sites of <italic>BMP2</italic>. It may bind with either positive or inhibitory transcriptional factors and result in aberrant expression of <italic>BMP2</italic>.</p><p>One case-control study showing <italic>BMP4</italic> rs17563 increased the expression of <italic>BMP4</italic> mRNA and associated with the risk of cutaneous melanoma [<xref rid="R19" ref-type="bibr">19</xref>]. In this study we didn't find association between <italic>BMP4</italic> rs17563 and RP in NSCLC patients and couldn't be able to validate the <italic>BMP4</italic> expression.</p><p>The ability to safely escalate radiation doses has long been considered important for patients with cancer given its established dose-response relationship [<xref rid="R20" ref-type="bibr">20</xref>, <xref rid="R21" ref-type="bibr">21</xref>]; however, results from the Radiation Therapy Oncology Group trial 0617 showed that a dose of 74 Gy (given in 2-Gy fractions with concurrent chemotherapy) not only was no better than 60 Gy with concurrent chemotherapy for patients with stage III NSCLC but also may have been harmful [<xref rid="R22" ref-type="bibr">22</xref>]. This result may have reflected limitations on the assessment of radiation-related toxicity and its contribution to treatment-related death. Therefore, it is crucial to identify patients who will benefit from higher radiation dose as well as those patients who are at high risk of developing radiation-related toxicity. Our inclusion of SNPs related to RP with dosimetric parameters related to RP represents a helpful tool for identifying those patients who are at increased risk of RP and thus may be less suitable for high-dose radiation. From the perspective of clinical practice, testing SNPs is inexpensive and relatively less invasive than analysis of tumor samples, as SNPs can be tested directly in peripheral blood samples, which expands the numbers of patients who can undergo this testing.</p><p>A strength of our study was the relatively large number of patients analyzed (663); indeed, this may be the largest study reported to date on associations between SNPs and RP in patients with NSCLC [<xref rid="R23" ref-type="bibr">23</xref>&#x02013;<xref rid="R25" ref-type="bibr">25</xref>]. We further tested the power of adding SNPs to the established clinical RP predictive model to investigate the predictive role of SNPs in the aspect of clinical practice.</p><p>However, this study also had some limitations. First, because it is a single institution retrospective study, these findings await for validation by other institutions and other patient populations. Second, we did not investigate the mechanisms underlying our positive results. Third, only potentially functional and tagging SNPs were studied, rather than all of the SNPs in the entire gene.</p><p>In conclusion, we found that SNPs in <italic>BMP2</italic> (rs235768, rs1980499, and rs3178250) can predict grade &#x02265; 2 or 3 RP after definitive radiotherapy for NSCLC, and including these SNPs in an existing model predicting RP risk based on age, performance status, and MLD could improve the predictive power.</p></sec><sec sec-type="methods" id="s4"><title>MATERIALS AND METHODS</title><sec id="s4_1"><title>Study population</title><p>This retrospective analysis was approved by the institutional review board of The University of Texas MD Anderson Cancer Center, and we complied with all applicable Health Insurance Portability and Accountability Act regulations. We searched an institutional database to identify patients who had received definitive radiotherapy for NSCLC at MD Anderson from 1999 through 2014 who had (1) histologically confirmed NSCLC; (2) received a total radiation dose of &#x02265; 60 Gy [or &#x02265; 60 Gy (RBE) for proton therapy]; (3) available computed tomography (CT) or positron emission tomography (PET) scans obtained within 1 year after completing radiotherapy, to be used for detecting and scoring RP; and (4) available archived blood samples for genotyping. Patients who had received stereotactic ablative radiotherapy were excluded. A total of 663 patients met these criteria and were the subjects of this analysis.</p><p>RP was assessed at each follow-up visit after the completion of radiotherapy and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 3.0. Follow-up visits took place within the first 1&#x02013;3 months after radiotherapy and then every 3 months thereafter for 2 years; those visits included interval history and physical examinations and imaging studies.</p></sec><sec id="s4_2"><title>SNP selection and genotyping methods</title><p>Potentially functional and tagging SNPs were selected by using <ext-link ext-link-type="uri" xlink:href="https://snpinfo.niehs.nih.gov/snpinfo/snpfunc.html">https://snpinfo.niehs.nih.gov/snpinfo/snpfunc.html</ext-link>. Predicted SNP functions are shown in <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 1</xref>. The inclusion criteria were: (1) a minor allele frequency of &#x0003e; 5% among whites; (2) located in a transcription factor binding site, a microRNA binding site, or a non-synonymous mutation in the coding area; and (3) an R<sup>2</sup> value for linkage disequilibrium between each SNP of &#x0003c; 0.8. Linkage disequilibrium was calculated with Haploview (<ext-link ext-link-type="uri" xlink:href="https://www.broadinstitute.org/scientific-community/science/programs/medical-and-population-genetics/haploview/haploview">https://www.broadinstitute.org/scientific-community/science/programs/medical-and-population-genetics/haploview/haploview</ext-link>) (Figure <xref ref-type="fig" rid="F3">3</xref>; numbers in the grid are R<sup>2 &#x000d7;</sup> 100).</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Linkage disequilibrium map for the single nucleotide polymorphisms studied</title><p>The numbers shown in the grid represent R<sup>2</sup> &#x000d7; 100 values. R<sup>2</sup> of our studied SNPs ranged from 0.09 to 0.72, all less than 0.80, indicating that our studies SNPs were not in high linkage disequilibrium.</p></caption><graphic xlink:href="oncotarget-08-43080-g003"/></fig><p>Genomic DNA was extracted from the buffy coat fraction of blood samples using a blood DNA mini kit. The genomic DNA was genotyping by Taqman real-time polymerase chain reaction. The extract of genomic DNA and genotyping methods were described in our previous study [<xref rid="R13" ref-type="bibr">13</xref>]. For all genotypes, the assay success rate was &#x0003e; 95%, and concordance of repeated sample testing was 100%.</p></sec><sec id="s4_3"><title>Statistical analyses</title><p>Chi-square tests were used to test for potential differences in distributions. Potential associations between RP risk and genotypes were assessed with a Cox proportional hazard model, with consideration of time to event. Characteristics with <italic>P</italic> values &#x0003c; 0.05 in the univariate Cox analysis were entered into the multivariate analysis; characteristics with a <italic>P value</italic> of &#x0003e; 0.20 in the multivariate analysis were then removed. Kaplan-Meier analysis was used to assess the effect of different genotypes on the cumulative probability of RP. All of these analyses were done with SPSS 22. Harrell's <italic>C</italic> was calculated to determine if adding SNPs that were found to be significant in the multivariate analyses could improve the ability of a model comprising age, performance status, and MLD to predict the risk of RP. All tests were 2-sided and differences were considered significant at <italic>P</italic> &#x0003c; 0.05.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>SUPPLEMENTARY TABLES</title><supplementary-material content-type="local-data" id="SD1"><media mimetype="application" mime-subtype="pdf" xlink:href="oncotarget-08-43080-s001.pdf" orientation="portrait" xlink:type="simple" id="d35e2580" position="anchor"/></supplementary-material></sec></body><back><ack><title>ACKNOWLEDGMENTS AND FUNDING</title><p>The China Scholarship Council financially supported Dr. Ju Yang during her stay in the department of Radiation Oncology, the University of Texas MD Anderson Cancer Center. This study is supported in part by Cancer Center Support (Core) Grant CA016672 from the US National Cancer Institute to The University of Texas MD Anderson Cancer Center.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>CONFLICTS OF INTEREST</bold></p><p>The authors do not see any conflicts of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torre</surname><given-names>LA</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Lortet-Tieulent</surname><given-names>J</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Global cancer statistics</article-title><source>CA Cancer J Clin</source><year>2015</year><volume>65</volume><fpage>87</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">25651787</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molina</surname><given-names>JR</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Cassivi</surname><given-names>SD</given-names></name><name><surname>Schild</surname><given-names>SE</given-names></name><name><surname>Adjei</surname><given-names>AA</given-names></name></person-group><article-title>Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship</article-title><source>Mayo Clin Proc</source><year>2008</year><volume>83</volume><fpage>584</fpage><lpage>594</lpage><pub-id pub-id-type="pmid">18452692</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schallenkamp</surname><given-names>JM</given-names></name><name><surname>Miller</surname><given-names>RC</given-names></name><name><surname>Brinkmann</surname><given-names>DH</given-names></name><name><surname>Foote</surname><given-names>T</given-names></name><name><surname>Garces</surname><given-names>YI</given-names></name></person-group><article-title>Incidence of radiation pneumonitis after thoracic irradiation: Dose-volume correlates</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2007</year><volume>67</volume><fpage>410</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">17236964</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>C</given-names></name><name><surname>Gomez</surname><given-names>DR</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Levy</surname><given-names>LB</given-names></name><name><surname>Zhuang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Nguyen</surname><given-names>Q</given-names></name><name><surname>Komaki</surname><given-names>R</given-names></name><name><surname>Liao</surname><given-names>Z</given-names></name></person-group><article-title>Association between white blood cell count following radiation therapy with radiation pneumonitis in non-small cell lung cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2014</year><volume>88</volume><fpage>319</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">24411603</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trott</surname><given-names>KR</given-names></name><name><surname>Herrmann</surname><given-names>T</given-names></name><name><surname>Kasper</surname><given-names>M</given-names></name></person-group><article-title>Target cells in radiation pneumopathy</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2004</year><volume>58</volume><fpage>463</fpage><lpage>469</lpage><pub-id pub-id-type="pmid">14751516</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>S</given-names></name><name><surname>Rubin</surname><given-names>P</given-names></name><name><surname>Phillips</surname><given-names>TL</given-names></name><name><surname>Marks</surname><given-names>LB</given-names></name></person-group><article-title>Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1995</year><volume>31</volume><fpage>1187</fpage><lpage>1203</lpage><pub-id pub-id-type="pmid">7713782</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahab</surname><given-names>NA</given-names></name><name><surname>Mason</surname><given-names>RM</given-names></name></person-group><article-title>A critical look at growth factors and epithelial-to-mesenchymal transition in the adult kidney. Interrelationships between growth factors that regulate EMT in the adult kidney</article-title><source>Nephron Exp Nephrol</source><year>2006</year><volume>104</volume><fpage>e129</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">16902316</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barthelemy-Brichant</surname><given-names>N</given-names></name><name><surname>Bosquee</surname><given-names>L</given-names></name><name><surname>Cataldo</surname><given-names>D</given-names></name><name><surname>Corhay</surname><given-names>JL</given-names></name><name><surname>Gustin</surname><given-names>M</given-names></name><name><surname>Seidel</surname><given-names>L</given-names></name><name><surname>Thiry</surname><given-names>A</given-names></name><name><surname>Ghaye</surname><given-names>B</given-names></name><name><surname>Nizet</surname><given-names>M</given-names></name><name><surname>Albert</surname><given-names>A</given-names></name><name><surname>Deneufbourg</surname><given-names>JM</given-names></name><name><surname>Bartsch</surname><given-names>P</given-names></name><name><surname>Nusgens</surname><given-names>B</given-names></name></person-group><article-title>Increased IL-6 and TGF-beta1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2004</year><volume>58</volume><fpage>758</fpage><lpage>767</lpage><pub-id pub-id-type="pmid">14967431</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Liao</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>LE</given-names></name><name><surname>Tucker</surname><given-names>SL</given-names></name><name><surname>Mao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>XS</given-names></name><name><surname>Martel</surname><given-names>M</given-names></name><name><surname>Komaki</surname><given-names>R</given-names></name><name><surname>Cox</surname><given-names>JD</given-names></name><name><surname>Milas</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name></person-group><article-title>Single nucleotide polymorphism at rs1982073: T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>3370</fpage><lpage>3378</lpage><pub-id pub-id-type="pmid">19380441</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Csiszar</surname><given-names>A</given-names></name><name><surname>Ahmad</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>KE</given-names></name><name><surname>Labinskyy</surname><given-names>N</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Kaley</surname><given-names>G</given-names></name><name><surname>Edwards</surname><given-names>JG</given-names></name><name><surname>Wolin</surname><given-names>MS</given-names></name><name><surname>Ungvari</surname><given-names>Z</given-names></name></person-group><article-title>Bone morphogenetic protein-2 induces proinflammatory endothelial phenotype</article-title><source>Am J Pathol</source><year>2006</year><volume>168</volume><fpage>629</fpage><lpage>638</lpage><pub-id pub-id-type="pmid">16436676</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>C</given-names></name><name><surname>Zhong</surname><given-names>N</given-names></name><etal/></person-group><article-title>Bone morphogenetic protein 4 inhibits liposaccharide-induced inflammation in the airway</article-title><source>Eur J Immunol</source><year>2014</year><volume>44</volume><fpage>3283</fpage><lpage>3294</lpage><pub-id pub-id-type="pmid">25142202</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selman</surname><given-names>M</given-names></name><name><surname>Pardo</surname><given-names>A</given-names></name><name><surname>Kaminski</surname><given-names>N</given-names></name></person-group><article-title>Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs?</article-title><source>PLoS Med</source><year>2008</year><volume>5</volume><fpage>e62</fpage><pub-id pub-id-type="pmid">18318599</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Gomez</surname><given-names>DR</given-names></name><name><surname>Jeter</surname><given-names>M</given-names></name><name><surname>Levy</surname><given-names>LB</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Hahn</surname><given-names>S</given-names></name><name><surname>Liao</surname><given-names>Z</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name></person-group><article-title>The Pulmonary Fibrosis Associated MUC5B Promoter Polymorphism Is Prognostic of the Overall Survival in Patients with Non-Small Cell Lung Cancer (NSCLC) Receiving Definitive Radiotherapy</article-title><source>Transl Oncol</source><year>2017</year><volume>10</volume><fpage>197</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">28189065</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>NH</given-names></name><name><surname>Li</surname><given-names>JJ</given-names></name><name><surname>Sun</surname><given-names>LQ</given-names></name></person-group><article-title>Molecular mechanisms and treatment of radiation-induced lung fibrosis</article-title><source>Curr Drug Targets</source><year>2013</year><volume>14</volume><fpage>1347</fpage><lpage>1356</lpage><pub-id pub-id-type="pmid">23909719</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosendahl</surname><given-names>A</given-names></name><name><surname>Pardali</surname><given-names>E</given-names></name><name><surname>Speletas</surname><given-names>M</given-names></name><name><surname>Ten Dijke</surname><given-names>P</given-names></name><name><surname>Heldin</surname><given-names>CH</given-names></name><name><surname>Sideras</surname><given-names>P</given-names></name></person-group><article-title>Activation of bone morphogenetic protein/Smad signaling in bronchial epithelial cells during airway inflammation</article-title><source>Am J Respir Cell Mol Biol</source><year>2002</year><volume>27</volume><fpage>160</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">12151307</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Jia</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Ge</surname><given-names>J</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name></person-group><article-title>Up-regulation of BMP-2 antagonizes TGF-beta1/ROCK-enhanced cardiac fibrotic signalling through activation of Smurf1/Smad6 complex</article-title><source>J Cell Mol Med</source><year>2012</year><volume>16</volume><fpage>2301</fpage><lpage>2310</lpage><pub-id pub-id-type="pmid">22283839</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Duan</surname><given-names>C</given-names></name><name><surname>Aronson</surname><given-names>JF</given-names></name><name><surname>Rastellini</surname><given-names>C</given-names></name><name><surname>Chao</surname><given-names>C</given-names></name><name><surname>Hellmich</surname><given-names>MR</given-names></name><name><surname>Ko</surname><given-names>TC</given-names></name></person-group><article-title>BMP2 inhibits TGF-beta-induced pancreatic stellate cell activation and extracellular matrix formation</article-title><source>Am J Physiol Gastrointest Liver Physiol</source><year>2013</year><volume>304</volume><fpage>G804</fpage><lpage>813</lpage><pub-id pub-id-type="pmid">23429583</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JM</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>BG</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>HC</given-names></name><name><surname>Wang</surname><given-names>YJ</given-names></name><name><surname>Song</surname><given-names>L</given-names></name></person-group><article-title>Uniaxial cyclic stretch promotes osteogenic differentiation and synthesis of BMP2 in the C3H10T1/2 cells with BMP2 gene variant of rs2273073 (T/G)</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e106598</fpage><pub-id pub-id-type="pmid">25191703</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capasso</surname><given-names>M</given-names></name><name><surname>Ayala</surname><given-names>F</given-names></name><name><surname>Russo</surname><given-names>R</given-names></name><name><surname>Avvisati</surname><given-names>RA</given-names></name><name><surname>Asci</surname><given-names>R</given-names></name><name><surname>Iolascon</surname><given-names>A</given-names></name></person-group><article-title>A predicted functional single-nucleotide polymorphism of bone morphogenetic protein-4 gene affects mRNA expression and shows a significant association with cutaneous melanoma in Southern Italian population</article-title><source>J Cancer Res Clin Oncol</source><year>2009</year><volume>135</volume><fpage>1799</fpage><lpage>1807</lpage><pub-id pub-id-type="pmid">19557432</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez</surname><given-names>CA</given-names></name><name><surname>Bauer</surname><given-names>M</given-names></name><name><surname>Edelstein</surname><given-names>S</given-names></name><name><surname>Gillespie</surname><given-names>BW</given-names></name><name><surname>Birch</surname><given-names>R</given-names></name></person-group><article-title>Impact of tumor control on survival in carcinoma of the lung treated with irradiation</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1986</year><volume>12</volume><fpage>539</fpage><lpage>547</lpage><pub-id pub-id-type="pmid">3009368</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Partridge</surname><given-names>M</given-names></name><name><surname>Ramos</surname><given-names>M</given-names></name><name><surname>Sardaro</surname><given-names>A</given-names></name><name><surname>Brada</surname><given-names>M</given-names></name></person-group><article-title>Dose escalation for non-small cell lung cancer: analysis and modelling of published literature</article-title><source>Radiother Oncol</source><year>2011</year><volume>99</volume><fpage>6</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">21458088</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradley</surname><given-names>JD</given-names></name><name><surname>Paulus</surname><given-names>R</given-names></name><name><surname>Komaki</surname><given-names>R</given-names></name><name><surname>Masters</surname><given-names>G</given-names></name><name><surname>Blumenschein</surname><given-names>G</given-names></name><name><surname>Schild</surname><given-names>S</given-names></name><name><surname>Bogart</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Forster</surname><given-names>K</given-names></name><name><surname>Magliocco</surname><given-names>A</given-names></name><name><surname>Kavadi</surname><given-names>V</given-names></name><name><surname>Garces</surname><given-names>YI</given-names></name><name><surname>Narayan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study</article-title><source>Lancet Oncol</source><year>2015</year><volume>16</volume><fpage>187</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">25601342</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>M</given-names></name><name><surname>Liao</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>LE</given-names></name><name><surname>Gomez</surname><given-names>D</given-names></name><name><surname>Komaki</surname><given-names>R</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name></person-group><article-title>Functional polymorphisms of base excision repair genes XRCC1 and APEX1 predict risk of radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2011</year><volume>81</volume><fpage>e67</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">21420246</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Kan</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Lv</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name></person-group><article-title>A study of ethnic differences in TGFbeta1 gene polymorphisms and effects on the risk of radiation pneumonitis in non-small-cell lung cancer</article-title><source>J Thorac Oncol</source><year>2012</year><volume>7</volume><fpage>1668</fpage><lpage>1675</lpage><pub-id pub-id-type="pmid">23059779</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>M</given-names></name><name><surname>Liao</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>LE</given-names></name><name><surname>O&#x02019;Reilly</surname><given-names>M</given-names></name><name><surname>Gomez</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Komaki</surname><given-names>R</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name></person-group><article-title>Genetic variants of the nonhomologous end joining gene LIG4 and severe radiation pneumonitis in nonsmall cell lung cancer patients treated with definitive radiotherapy</article-title><source>Cancer</source><year>2012</year><volume>118</volume><fpage>528</fpage><lpage>535</lpage><pub-id pub-id-type="pmid">21717429</pub-id></element-citation></ref></ref-list></back></article>